Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol.
Vera J G M Vaessen, Ralf L O van de Laar, Marta Piso-Jozwiak...
https://pubmed.ncbi.nlm.nih.gov/40394508/Actively Recruiting
Led by Erasmus Medical Center · Updated on 2026-09-15
500
Participants Needed
1
Research Sites
104 weeks
Total Duration
Researchers are evaluating the effectiveness of the nonavalent HPV vaccine in preventing recurrence of vulvar High Grade Squamous Intraepithelial Lesion vHSIL, a premalignant condition related to HPV that affects women, mainly between ages 35 and 40. Vulvar HSIL has a high recurrence rate after treatment, leading to repeated interventions and increased risk of vulvar cancer. This study aims to compare HPV vaccination with placebo to reduce recurrences and improve quality of life. Participants will be randomly assigned to receive either three doses of the Gardasil 9 vaccine or placebo injections, administered around their planned treatment for vHSIL, which may include surgery, laser, or topical imiquimod. The vaccination schedule involves a first injection near treatment start, a second injection at least one month later, and a third injection three months after the second, all within one year. During the study, women will be monitored for recurrence of vHSIL up to 24 months after inclusion, with evaluations at 6, 12, and 24 months, including quality of life and sexual health assessments. Additional long-term follow-up will assess recurrence and cancer development over 5 to 10 years. Researchers will also measure antibody levels, HPV types, treatment effectiveness, and cost-effectiveness. Safety and recurrence data will be closely observed throughout the study duration.
CONDITIONS
Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Erasmus Medical Center
Lead Sponsor
Dutch Cancer Society
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive planned treatment for vulvar HSIL (surgery, laser, or topical imiquimod) along with three injections of either Gardasil 9 vaccine or placebo over one year.
3 vaccination visits over 12 months
Duration - Up to 10 years
Participants are monitored for recurrence of vulvar HSIL and assessed for quality of life, sexual health, antibody levels, and HPV type changes for up to 24 months after last inclusion. Long-term follow-up may continue up to 10 years to observe recurrence and cancer development.
Regular follow-up visits at 6, 12, 24 months and extended monitoring
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Vera J G M Vaessen, Ralf L O van de Laar, Marta Piso-Jozwiak...
https://pubmed.ncbi.nlm.nih.gov/40394508/Erasmus Medical Center
Lead Sponsor
Dutch Cancer Society
Collaborating Sponsor